

Response Under 37 CFR 1.116
Expedited Procedure
Examining Group 1647
Application No. 09/806,178
Paper Dated: August 5, 2003
In Reply to USPTO Correspondence of May 5, 2003
Attorney Docket No. 0702-010411

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-6 (cancelled).

Claim 7 (currently amended): A method for the treatment of focal cerebral ischemic infarction by administering in an effective dosage amount of between about 1.5 to 7.0 mg/kg body weight of at least one α_2 -antiplasmin neutralizing compound.

Claim 8-11 (cancelled).

Claim 12 (previously presented): The method according to claim 7, wherein the at least one compound is an α_2 -antiplasmin neutralizing compound selected from the group consisting of plasmin, mini-plasmin (lacking the first four kringles) or micro-plasmin (lacking all five kringles).

Claim 13 (previously presented): The method of claim 7, wherein the at least one α_2 -antiplasmin neutralizing compound contains the catalytic domain of plasmin.

Claim 14 (previously presented): The method of claim 13, wherein the at least one α_2 -antiplasmin neutralizing compound contains a structure selected from the group consisting of at least one Kringle domain of plasmin and mutants and hybrids thereof.

Claim 15 (cancelled).